France has written to approximately 1.6 million women about a tumour risk linked to their contraceptive pill. The medicine remains on sale there and elsewhere in Europe. Different approaches to informing patients can leave women unaware of the risk or alarmed enough to stop contraception without arranging an alternative.
For one 30-year-old French woman, the warning led to a switch. “My clinician told me we will need to change the pill. You could see he was pretty urgent about it,” she said. She is not named because of the sensitivity of her medical information.
Her account concerns desogestrel, a hormone used in contraceptives sold under names including Cerazette, Optimizette and Antigone. European regulators recommended tighter warnings and prescribing restrictions in July. France subsequently used health-insurance records to contact adult users of the 75-microgram pill directly.
Yet the letter sent to women also says: “Continue your contraception normally: do not stop it without medical advice.” The message, translated from French, captures the difficult position patients face. They have been told about a potentially serious consequence, while being advised to continue until they can discuss their circumstances.
A warning reaches French women directly
The warning follows a French study published in the medical journal BMJ comparing 8,391 women who underwent surgery for meningioma with 83,910 women without that diagnosis. Meningiomas develop in the tissue surrounding the brain and spinal cord. They are usually non-cancerous, but can cause serious neurological problems and require surgery. Researchers found a small increased risk associated with prolonged desogestrel use, particularly beyond five continuous years.
The study estimated one additional case of meningioma requiring surgery per approximately 67,300 women exposed overall, rising to roughly one per 17,000 after more than five years. These are study-derived estimates, not annual rates. The excess risk was no longer observed a year after discontinuation. The risk was also greater among women previously exposed to certain other hormone treatments.
Continue your contraception normally: do not stop it without medical advice. — ANSM letter to patients
European Medicines Agency’s (EMA) safety committee recommended warnings for desogestrel and the related hormone etonogestrel, used in implants and some vaginal rings. These medicines should not be used by women with a current or previous meningioma, and treatment must stop if one is diagnosed.
The direct research concerned desogestrel; etonogestrel was included because desogestrel is converted into it in the body. The same numerical risk was not directly established for every product covered.
France’s distinctive step was to put the information directly into identifiable patients’ hands. Its regulator, ANSM, describes the letters as an addition to earlier professional warnings. The campaign was not a recall or a ban. Nor did receiving a letter mean a tumour had been diagnosed or suspected. But it brought a European safety finding into women’s everyday decisions about a medicine many had taken for years.
Common safety rules, uneven routes to information
The European response was not limited to notices buried on websites. The Dutch medicines regulator documented letters to doctors, midwives and pharmacists. Germany’s BfArM published the warning, and Czechia’s SÚKL issued recommendations for physicians to minimise risks. These channels establish action, but do not show how many women actually received or understood the information.
Even France’s direct campaign had limits. ANSM told medical reference publisher VIDAL that it focused on the 75-microgram pills examined in the study. Some other contraceptives covered by the broader warning are not reimbursed, making their users unidentifiable through insurance records. A shared safety message therefore does not automatically mean every patient can be reached in the same way.
The case also resists a blanket verdict on hormonal contraception. The study did not find the same increased meningioma risk with the levonorgestrel formulations it examined. Different products have different benefits and risks. Switching treatment requires more than removing one warning from the equation, particularly when contraception also helps manage menstrual symptoms.
The sharper criticism is about what happens after Europe identifies a risk. Updating a leaflet and notifying prescribers are necessary steps, but their success depends on understandable information and access to an individual discussion. France’s letters brought the warning directly to women. Continued sales leave an obligation beyond the warning itself: ensuring that women can make an informed choice about a medicine they are still being offered.
Why the pill remains on sale
A medicine’s approval is not a promise that no further risks will emerge. European safety monitoring continues after it reaches the market, using evidence from wider and longer-term use. Authorities can update warnings, restrict prescribing, suspend an authorisation or withdraw a medicine. The assessment asks whether its benefits outweigh its risks under the conditions in which it is used.
For desogestrel, the response has been to retain access while changing prescribing and monitoring. That does not dismiss the harm experienced by women who develop a tumour. It means regulators have chosen restrictions rather than a general withdrawal, leaving clinicians and patients to assess whether continued use remains appropriate. A decision made across a population must then be translated into a decision for an individual woman.
My clinician told me we will need to change the pill. — French woman on desogestrel treatment
Manufacturers have also communicated the risk. In Ireland, Organon, Gedeon Richter and Sandoz issued a joint letter agreed with EMA and the national regulator. “Women treated with desogestrel or etonogestrel should be monitored for signs and symptoms of meningioma,” it states. The document sets out restrictions and reporting requirements; it is not an announcement that the products will leave the market.
France’s doctors have warned about the consequences of poorly understood advice. In an 8 October statement, the Collège de la Médecine Générale said patients were sometimes “caught between conflicting advice”, in translation. It favours continued use in women without a history of meningioma or suggestive symptoms, while calling for shared decisions in consultations.
Separately, the national gynaecologists’ organisation said the findings did not justify an urgent contraceptive change. The anonymous patient’s account shows that individual advice can nevertheless feel considerably more pressing.
